Dynex Capital reported Q3 2026 earnings per share of $0.38, just below the $0.39 analyst estimate, while revenue came in at $101.6 million, missing the $113.5 million forecast. Despite a slight EPS increase from the prior quarter, revenue dropped significantly from $302.75 million to $101.6 million. This revenue shortfall highlights challenges in Dynex's mortgage-backed securities investments. The company held a conference call to discuss these results and future outlook.
Dynex Capital's Q3 2026 revenue was $101.6 million, significantly below the $113.5 million analyst forecast. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 19, 2026 22:42 WIB: out of 142 priced Financials-sector US stocks tradable on Pluang, 46 rose and 96 fell today. Notable movers include HDB at USD 23.05 with a 1-day change of -3.31%, PSEC at USD 1.55 down 3.13%, and HUT at USD 69.79 up 3.01%.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
